Search

Your search keyword '"Auerbach, Michael"' showing total 384 results
Start Over Author "Auerbach, Michael" Publication Type Academic Journals
384 results on '"Auerbach, Michael"'

3. RAPIDIRON Trial follow-up study — the RAPIDIRON-KIDS Study: protocol of a prospective observational follow-up study

Author

Derman, Richard J., Bellad, Roopa B., Bellad, Mrutyunjaya B., Bradford-Rogers, Jesse, Georgieff, Michael K., Aghai, Zubair H., Thind, Simal, Auerbach, Michael, Boelig, Rupsa, Leiby, Benjamin E., Short, Vanessa, Yogeshkumar, S., Charantimath, Umesh S., Somannavar, Manjunath S., Mallapur, Ashalata A., Pol, Ramesh, Ramadurg, Umesh, Sangavi, Radha, Peerapur, Basavaraj V., Banu, Nasima, Patil, Praveen S., Patil, Amaresh P., Roy, Subarna, Vastrad, Phaniraj, Wallace, Dennis, Shah, Hemang, and Goudar, Shivaprasad S.

Published
2023
Full Text
View/download PDF

4. Protocol for a multicenter, double-blinded placebo-controlled randomized controlled trial comparing intravenous ferric derisomaltose to oral ferrous sulfate for the treatment of iron deficiency anemia in pregnancy: The IVIDA2 trial

Author

Lewkowitz, Adam K., Stout, Molly J., Carter, Ebony B., Ware, Crystal F., Jackson, Tracy L., D'Sa, Viren, Deoni, Sean, Odibo, Anthony O., Gopalakrishnan, Riley, Liu, Jingxia, Rouse, Dwight J., Auerbach, Michael, and Tuuli, Methodius G.

Published
2022
Full Text
View/download PDF

6. Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)

Author

Shander, Aryeh, Corwin, Howard L., Meier, Jens, Auerbach, Michael, Bisbe, Elvira, Blitz, Jeanna, Erhard, Jochen, Faraoni, David, Farmer, Shannon L., Frank, Steven M., Girelli, Domenico, Hall, Tiffany, Hardy, Jean-François, Hofmann, Axel, Lee, Cheuk-Kwong, Leung, Tsin W., Ozawa, Sherri, Sathar, Jameela, Spahn, Donat R., Torres, Rosalio, Warner, Matthew A., and Muñoz, Manuel

Published
2023
Full Text
View/download PDF

7. Recommendations from the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)

Author

Shander, Aryeh, Corwin, Howard L., Meier, Jens, Auerbach, Michael, Bisbe, Elvira, Blitz, Jeanna, Erhard, Jochen, Faraoni, David, Farmer, Shannon, Frank, Steven M., Girelli, Domenico, Hall, Tiffany, Hardy, Jean-François, Hofmann, Axel, Lee, Cheuk-Kwong, Leung, Tsin Wah, Ozawa, Sherri, Sathar, Jameela, Spahn, Donat R., Torres, Rosalio, Warner, Matthew A., and Muñoz, Manuel

Published
2022
Full Text
View/download PDF

11. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Author

Macdougall, Iain C, Bircher, Andreas J, Eckardt, Kai-Uwe, Obrador, Gregorio T, Pollock, Carol A, Stenvinkel, Peter, Swinkels, Dorine W, Wanner, Christoph, Weiss, Günter, Chertow, Glenn M, Participants, Conference, Adamson, John W, Akizawa, Tadao, Anker, Stefan D, Auerbach, Michael, Bárány, Peter, Besarab, Anatole, Bhandari, Sunil, Cabantchik, Ioav, Collins, Alan J, Coyne, Daniel W, de Francisco, Ángel LM, Fishbane, Steven, Gaillard, Carlo AJM, Ganz, Tomas, Goldsmith, David J, Hershko, Chaim, Jankowska, Ewa A, Johansen, Kirsten L, Kalantar-Zadeh, Kamyar, Kalra, Philip A, Kasiske, Bertram L, Locatelli, Francesco, Małyszko, Jolanta, Mayer, Gert, McMahon, Lawrence P, Mikhail, Ashraf, Nemeth, Elizabeta, Pai, Amy Barton, Parfrey, Patrick S, Pecoits-Filho, Roberto, Roger, Simon D, Rostoker, Guy, Rottembourg, Jacques, Singh, Ajay K, Slotki, Itzchak, Spinowitz, Bruce S, Tarng, Der-Cherng, Tentori, Francesca, Toblli, Jorge E, Tsukamoto, Yusuke, Vaziri, Nosratola D, Winkelmayer, Wolfgang C, Wheeler, David C, and Zakharova, Elena

Subjects
Hematology, Digestive Diseases, Nutrition, Kidney Disease, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Cardiovascular Diseases, Ferritins, Hematinics, Hemoglobins, Hepcidins, Humans, Hypersensitivity, Infections, Iron, Iron Deficiencies, Iron Overload, Oxidative Stress, Renal Insufficiency, Chronic, chronic kidney disease, hypersensitivity, infections, iron, overload, oxidative stress, Conference Participants, Clinical Sciences, Urology & Nephrology
Abstract

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.

Published
2016

18. Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials.

Author

Lim, Jayne, Auerbach, Michael, MacLean, Beth, Al-Sharea, Annas, and Richards, Toby

Subjects
*INTRAVENOUS therapy, *RANDOMIZED controlled trials, *IRON deficiency anemia, *ANEMIA, *IRON, *MOSQUITO nets, *RADIOTHERAPY
Abstract

Anemia is a common problem when patients present with cancer, and it can worsen during treatment. Anemia can directly impact the cognitive and physical quality of life and may impair fitness for oncological therapy. The most common cause of anemia is iron deficiency. Newer intravenous (IV) iron formulations offer a safe and rapidly effective treatment option. We performed a systematic mapping review of randomized controlled trials (RCTs) evaluating intravenous iron therapy in patients with cancer and anemia and their outcomes. A total of 23 RCTs were identified. The median number of patients enrolled was 104 (IQR: 60–134). A total of 5 were focused on surgical outcomes (4 preoperative, 1 postoperative), and 15 were in adjuvant therapies for a variety of tumor types (breast, colorectal, lung, gynecological, myeloid, and lymphomas), 10 of which were in combination with erythropoietin-stimulating agents (ESAs) therapy, 2 in radiotherapy, and 1 in palliative care. Overall, the studies reported that the use of IV iron increased hemoglobin concentration and decreased transfusion rates during different cancer treatment regimes. IV iron can be administered safely throughout the cancer treatment pathway from primary surgery to the palliative setting. More studies are needed to demonstrate net clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Optimizing diagnosis and treatment of iron deficiency and iron deficiency anemia in women and girls of reproductive age: Clinical opinion.

Author

Auerbach, Michael

Subjects
*IRON deficiency anemia, *CHILDBEARING age, *IRON deficiency, *ACUTE phase proteins, *FIRST trimester of pregnancy
Abstract

Iron deficiency (ID) is the world's most common disorder and one of the top five causes of years lived with disability. Whereas low serum ferritin is diagnostic of ID, ferritin—an acute phase reactant—may be elevated in inflammatory states and the first trimester of pregnancy even if ID exists. Consequently, in early pregnancy or chronic inflammation, percent transferrin saturation (TSAT) measurement is the best indicator of iron status. Unfortunately, current guidelines do not recommend routine screening for ID in either pregnant or nonpregnant women in the absence of anemia. This circumstance should be urgently reviewed based on available data. While oral formulations have long been the standard for iron replacement therapy and are widely available and inexpensive, oral iron is frequently associated with adverse gastrointestinal effects for the majority—a major reason for poor adherence, inadequate repletion, and persisting ID symptoms and sequellae. Although safe intravenous iron administration was introduced in the mid‐1950s, formulations with cores binding the elemental iron more tightly became available in the 2000s, allowing complete and safe replacement, even in a single setting. Prospectively acquired neonatology evidence reports oral iron's failure to reach the developing fetus when the mother is iron deficient. Consequently, while oral iron remains frontline in the first trimester because of insufficient safety data for intravenous iron, the author recommends that the intravenous route should be the gold standard for second‐trimester ID when hemoglobin concentrations are less than 10.5 g/dL and for all iron‐deficient women in their third trimester. Synopsis: The treatment of iron deficiency and iron deficiency anemia in reproductive‐aged women and girls requires revisiting and represents an unmet clinical need. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Caloric availability of polydextrose

Author

Auerbach, Michael H., Craig, Stuart A.S., Howlett, John F., and Hayes, Kenneth C.

Subjects
Polydextrose -- Research, Food/cooking/nutrition
Abstract

Polydextrose is a randomly bonded polysaccharide produced by the bulk melt polycondensation of glucose and sorbitol in vacuo. It has been used as a bulking and texturizing agent and soluble fiber ingredient in many food products worldwide for over two decades. Because of its atypical linkages between glucose moieties, polydextrose resists digestion by mammalian gastrointestinal enzymes. It is minimally absorbed in the small intestine and partially fermented in the large intestine producing volatile fatty acids, with approximately 50% of the ingested dose being excreted undigested. In this it is similar to many other poorly digested soluble fiber ingredients. Numerous energy balance and isotope-label disposition studies have been conducted in animals and man to investigate the caloric availability of polydextrose. The weight of available experimental evidence in the 14 studies described herein shows that polydextrose has a caloric value of approximately 1 kcal/g. Key words: calories, energy balance, isotope label disposition, polydextrose doi: 10.1301/nr.2007.dec.544-549

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results